The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol


Protect Our Communities! Share Your Concerns With Gilead About Their New Prevention Trial

November 16, 2016

Gilead has recently launched a prevention study testing the safety and efficacy of F/TAF (Descovy) as PrEP. This drug is already being used for treatment for people living with HIV, and the drug maker wants to see if it works as prevention for HIV-negative people.

We are all for research into new methods of HIV prevention, but community advocates from North America and across Europe, including HIV PJA, are deeply concerned about Gilead's failure to follow internationally agreed upon guidelines known as Good Participatory Practice (GPP).

Why Our Concern?

Gilead has never conducted this kind of large HIV prevention trial and, so far, has shown a lack of understanding around the critical role of community engagement. HIV organizations in the United States, Canada and several countries in Europe, where the trial is already underway or planned to start, are asking Gilead to temporarily halt the trial until all of the necessary protections are put in place.

These include following the GPP guidelines closely and ensuring that people at increased risk of HIV are connected to services to discuss their risk, to learn important information about PrEP and decide what is best for them as individuals.

Help protect our communities. Read the letter and sign your organization on as an endorser.

Check out this fact sheet to learn more about the trial.

Related Stories

Why Are HIV Groups Charging Gilead With Bad Behavior in New PrEP Trial?
More Calls to Action

This article was provided by HIV Prevention Justice Alliance. Visit HIV Prevention Justice Alliance's website to find out more about their activities and publications.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.